532300 Stock Overview
A pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,515.10 |
| 52 Week High | ₹1,678.60 |
| 52 Week Low | ₹422.00 |
| Beta | 1.72 |
| 1 Month Change | 14.92% |
| 3 Month Change | 29.40% |
| 1 Year Change | 238.57% |
| 3 Year Change | 292.11% |
| 5 Year Change | 312.05% |
| Change since IPO | 675.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532300 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -8.3% | -2.7% | -4.0% |
| 1Y | 238.6% | 13.6% | 3.4% |
Return vs Industry: 532300 exceeded the Indian Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: 532300 exceeded the Indian Market which returned 3.4% over the past year.
Price Volatility
| 532300 volatility | |
|---|---|
| 532300 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 532300's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 532300's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,386 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices.
Wockhardt Limited Fundamentals Summary
| 532300 fundamental statistics | |
|---|---|
| Market cap | ₹245.67b |
| Earnings (TTM) | -₹1.91b |
| Revenue (TTM) | ₹30.01b |
8.2x
P/S Ratio-128.6x
P/E RatioIs 532300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532300 income statement (TTM) | |
|---|---|
| Revenue | ₹30.01b |
| Cost of Revenue | ₹12.33b |
| Gross Profit | ₹17.68b |
| Other Expenses | ₹19.59b |
| Earnings | -₹1.91b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.76 |
| Gross Margin | 58.91% |
| Net Profit Margin | -6.36% |
| Debt/Equity Ratio | 63.1% |
How did 532300 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 19:19 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wockhardt Limited is covered by 19 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |